Current Report Filing (8-k)
November 13 2017 - 4:15PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date
of Report: November 13, 2017
(Date of earliest event reported)
ImmuCell
Corporation
(Exact name of registrant as specified in its charter)
DE
|
|
001-12934
|
|
01-0382980
|
(State
or other jurisdiction
of incorporation)
|
|
(Commission File Number)
|
|
(IRS
Employer
Identification Number)
|
56 Evergreen Drive
Portland, Maine
|
|
04103
|
(Address of principal executive offices)
|
|
(Zip Code)
|
207-878-2770
(Registrant's telephone number, including
area code)
Not
Applicable
(Former Name or Former Address, if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant
under any of the following provisions:
☐ Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item
2.02. Results of Operations and Financial Condition
On
November 13, 2017 ImmuCell Corporation (the "Company") issued a press release announcing unaudited financial results
for the three-month and nine-month periods ended September 30, 2017. The full text of the press release issued in connection with
the announcement is attached as Exhibit 99.1 to this Current Report on Form 8-K.
The
information shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange
Act") or otherwise subject to liabilities of that section, nor shall it be deemed incorporated by reference in any filing
under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such filing.
Item
9.01. Financial Statements and Exhibits.
(d)
|
Exhibits
.
|
|
|
|
The
following exhibit relating to Item 2.02 shall be deemed to be furnished, and not filed:
|
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
IMMUCELL
CORPORATION
|
|
|
Date:
November 13, 2017
|
By:
|
/s/
Michael F. Brigham
|
|
|
Michael
F. Brigham
|
|
|
President, Chief Executive Officer and
Principal Financial Officer
|
Exhibit Index
4
ImmuCell (NASDAQ:ICCC)
Historical Stock Chart
From Mar 2024 to Apr 2024
ImmuCell (NASDAQ:ICCC)
Historical Stock Chart
From Apr 2023 to Apr 2024